Jacobio (1167) Announces Positive Phase I/IIa Results for KRAS G12C + SHP2 Inhibitor Combination

Bulletin Express12-01

Jacobio Pharmaceutical Group Co., Ltd. (Stock code: 1167) announced that the Phase I/IIa clinical study of glecirasib (its KRAS G12C inhibitor) in combination with the SHP2 inhibitor JAB-3312 (sitneprotafib) has been published in The Lancet Respiratory Medicine. This marks the first comprehensive clinical data release of an all-oral KRAS G12C + SHP2 inhibitor combination in a top-tier medical journal.

The open-label study enrolled 171 patients in China with KRAS G12C–mutated non-small cell lung cancer (NSCLC), including 102 who had not received prior treatment. The combination therapy achieved a 71% objective response rate and 12.2 months median progression-free survival in the first-line population. A Phase III clinical trial comparing this dual oral combination with the existing standard of care has already commenced in China.

Jacobio focuses on novel molecular targets across six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB, and MYC. The company operates R&D centers in Beijing, Shanghai, and Boston, applying its Induced Allosteric Drug Discovery Platform (IADDP) and immunostimulatory antibody-drug conjugate (iADC) platform to further its pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121551067?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 08:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121551067","market":"us","top_or_hot":-1,"title":"Jacobio (1167) Announces Positive Phase I/IIa Results for KRAS G12C + SHP2 Inhibitor Combination","media":"Bulletin Express","content":"<p>Jacobio Pharmaceutical Group Co., Ltd. (Stock code: 1167) announced that the Phase I/IIa clinical study of glecirasib (its KRAS G12C inhibitor) in combination with the SHP2 inhibitor JAB-3312 (sitneprotafib) has been published in The Lancet Respiratory Medicine. This marks the first comprehensive clinical data release of an all-oral KRAS G12C + SHP2 inhibitor combination in a top-tier medical journal.</p>\n<p>The open-label study enrolled 171 patients in China with KRAS G12C–mutated non-small cell lung cancer (NSCLC), including 102 who had not received prior treatment. The combination therapy achieved a 71% objective response rate and 12.2 months median progression-free survival in the first-line population. A Phase III clinical trial comparing this dual oral combination with the existing standard of care has already commenced in China.</p>\n<p>Jacobio focuses on novel molecular targets across six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB, and MYC. The company operates R&D centers in Beijing, Shanghai, and Boston, applying its Induced Allosteric Drug Discovery Platform (IADDP) and immunostimulatory antibody-drug conjugate (iADC) platform to further its pipeline.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jacobio (1167) Announces Positive Phase I/IIa Results for KRAS G12C + SHP2 Inhibitor Combination</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJacobio (1167) Announces Positive Phase I/IIa Results for KRAS G12C + SHP2 Inhibitor Combination\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-12-01 08:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jacobio Pharmaceutical Group Co., Ltd. (Stock code: 1167) announced that the Phase I/IIa clinical study of glecirasib (its KRAS G12C inhibitor) in combination with the SHP2 inhibitor JAB-3312 (sitneprotafib) has been published in The Lancet Respiratory Medicine. This marks the first comprehensive clinical data release of an all-oral KRAS G12C + SHP2 inhibitor combination in a top-tier medical journal.</p>\n<p>The open-label study enrolled 171 patients in China with KRAS G12C–mutated non-small cell lung cancer (NSCLC), including 102 who had not received prior treatment. The combination therapy achieved a 71% objective response rate and 12.2 months median progression-free survival in the first-line population. A Phase III clinical trial comparing this dual oral combination with the existing standard of care has already commenced in China.</p>\n<p>Jacobio focuses on novel molecular targets across six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB, and MYC. The company operates R&D centers in Beijing, Shanghai, and Boston, applying its Induced Allosteric Drug Discovery Platform (IADDP) and immunostimulatory antibody-drug conjugate (iADC) platform to further its pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01167","symbol_name":"加科思-B","start_time":0,"source_url":"","article_id":"1121551067","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121551067","pubTimestamp":1764548560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Jacobio Pharmaceutical Group Co., Ltd. (Stock code: 1167) announced that the Phase I/IIa clinical study of glecirasib (its KRAS G12C inhibitor) in combination with the SHP2 inhibitor JAB-3312...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01167":"加科思-B"},"translate_title":"雅可比奥（1167）公布KRAS G12C+SHP2抑制剂组合I/IIa期阳性结果","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":1},"content_text":"Jacobio Pharmaceutical Group Co., Ltd. (Stock code: 1167) announced that the Phase I/IIa clinical study of glecirasib (its KRAS G12C inhibitor) in combination with the SHP2 inhibitor JAB-3312 (sitneprotafib) has been published in The Lancet Respiratory Medicine. This marks the first comprehensive clinical data release of an all-oral KRAS G12C + SHP2 inhibitor combination in a top-tier medical journal.\nThe open-label study enrolled 171 patients in China with KRAS G12C–mutated non-small cell lung cancer (NSCLC), including 102 who had not received prior treatment. The combination therapy achieved a 71% objective response rate and 12.2 months median progression-free survival in the first-line population. A Phase III clinical trial comparing this dual oral combination with the existing standard of care has already commenced in China.\nJacobio focuses on novel molecular targets across six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB, and MYC. The company operates R&D centers in Beijing, Shanghai, and Boston, applying its Induced Allosteric Drug Discovery Platform (IADDP) and immunostimulatory antibody-drug conjugate (iADC) platform to further its pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121551067","isCrawlerRequest":true}